Arietis

What Arietis does

Arietis Corporation is a privately held, pre-clinical biotechnology company founded in 2006 and headquartered at the Bio Square Discovery and Innovation Center on Boston University's Medical Campus. The company is developing first-in-class small molecule antibiotics that activate the bacterial ClpP protease, forcing cells to self-digest. This mechanism is designed to kill drug-resistant Gram-positive ESKAPE pathogens — including Staphylococcus aureus (MRSA), Enterococcus faecium (VRE), and drug-resistant Streptococcus pneumoniae — and is differentiated from traditional antibiotics by its activity against non-growing persister cells and biofilms, where conventional therapies fail.

The company was founded on antimicrobial discovery technologies developed by Professor Kim Lewis at Northeastern University's Antimicrobial Discovery Center, and operates as a tightly resourced research organization of 1-10 employees led by CEO Dr. Michael LaFleur, a co-inventor on key Arietis technology. Arietis communicates primarily through peer-reviewed publications in journals such as Nature, ACS Infectious Diseases, and Antimicrobial Agents and Chemotherapy, and has no commercial products, disclosed revenue, or institutional investors identified in available sources. Its go-to-market path will require IND-enabling studies, regulatory designations such as FDA QIDP, and ultimately either a development partnership or out-licensing arrangement to advance candidates into clinical trials.

Name

Arietis

Legal name

Arietis Corporation

Website

https://arietis.org

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

Arietis is a pre-clinical biotechnology company developing first-in-class small-molecule antibiotics that activate the bacterial ClpP protease to kill drug-resistant Gram-positive pathogens such as MRSA, VRE, and drug-resistant S. pneumoniae.

Ownership category

akta.pro rank

Product category

Antibiotic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYHLAIAAAG

Infectious Disease & Antimicrobials Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Novel antibiotic discovery
• Antimicrobial drug development
• ClpP protease activators
• Drug-resistant pathogen therapy
• Gram-positive infection treatment

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Marketing channels2 records

Core offering

Arietis is developing first-in-class small-molecule antibiotics that activate the bacterial ClpP protease, causing cells to self-digest. The compounds are designed to rapidly kill highly resistant Gram-positive ESKAPE pathogens — including Staphylococcus aureus, Enterococcus faecium, and drug-resistant Streptococcus pneumoniae — including non-growing persister cells and biofilms that traditional antibiotics cannot eliminate. The pipeline is currently at the pre-clinical stage, with no commercially marketed products.

Product overview

Arietis is developing a single core product: ClpP Activating Antibiotics. These novel small molecule antibiotics represent a first-in-class approach that activates the ClpP protease to cause bacterial cells to self-digest. The technology is specifically designed to kill drug-resistant Gram-positive pathogens including MRSA, VRE, and drug-resistant S. pneumoniae. Unlike traditional antibiotics that target processes inactive in non-growing cells, ClpP activators can eliminate persisters and eradicate biofilms where conventional antibiotics fail.

Differentiator

Problem solved

Functional benefit

Products and services

• ClpP Activating Antibiotics Proprietary, first-in-class small-molecule antibiotics that activate the bacterial ClpP protease, causing cells to self-digest. Designed to rapidly kill drug-resistant ESKAPE Gram-positive pathogens including Staphylococcus aureus, Enterococcus faecium, and drug-resistant Streptococcus pneumoniae, including non-growing persister cells and biofilms. Currently at the pre-clinical stage; intended for healthcare providers and patients with complicated drug-resistant infections (prosthetic joint infections, endocarditis, osteomyelitis, diabetic ulcers, catheter-related infections, and acute bacterial respiratory infections).

Quantifiable outcome

• Eradication of MRSA infections in animal models where traditional antibiotics failed due to biofilms

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Northeastern UniversitycoreStrategic or Co-development PartnerArietis was founded on technologies for discovering antimicrobials developed by Professor Kim Lewis at Northeastern University. Dr. Lewis serves as Founder & Chairman of the Board. The company is located at Boston University's Medical Campus, suggesting ongoing academic partnerships.

Recent moves5 records

Expansion highlights3 records

Direct peers

• Entasis Therapeutics: Clinical-stage antibacterial developer (now part of Innoviva) targeting drug-resistant Gram-negative and Gram-positive infections. Direct peer given comparable mission of developing first-in-class antibiotics for highly resistant ESKAPE-class pathogens.
• Iterum Therapeutics: Public clinical-stage company developing oral and IV antibiotics (sulopenem) against multi-drug resistant Gram-negative and Gram-positive pathogens. Direct peer in the novel antibacterial development space serving similar unmet needs.
• VenatoRx Pharmaceuticals: Private clinical-stage developer of novel antibiotics targeting drug-resistant Gram-negative and Gram-positive bacteria, including MRSA and VRE. Closely comparable as a small, science-driven antibacterial company pursuing differentiated mechanisms.
• Bioversys: Swiss private clinical-stage antibacterial company developing small molecules to address drug resistance and biofilm-driven infections. Direct peer with a comparable small-molecule, resistance-reversal approach to ESKAPE pathogens.

Emerging players

• Cidara Therapeutics: Clinical-stage developer of antifungal and antibacterial conjugates (Cloudbreak platform) targeting drug-resistant infections. Emerging peer with overlapping antimicrobial resistance focus, though primarily antifungal.
• Nabriva Therapeutics: Developer of lefamulin (Xenleta), an approved pleuromutilin antibiotic for community-acquired bacterial pneumonia. Emerging peer with overlapping Gram-positive pathogen focus (including resistant S. pneumoniae).
• Procarta Biosystems: Early-stage antibacterial developer of precision antimicrobial oligonucleotide and small-molecule therapeutics targeting drug-resistant ESKAPE pathogens. Emerging peer with a comparable novel-mechanism antibacterial thesis.
• Eligo Bioscience: Emerging player developing engineered bacteriophage-based antimicrobials (eligobiotics) to selectively kill drug-resistant bacteria. Comparable as a next-generation antimicrobial platform tackling AMR with a novel mechanism.

Broad incumbents

• Melinta Therapeutics: Established developer/marketer of antibiotics including delafloxacin (Baxdela) and meropenem/vaborbactam (Vabomere). Broad incumbent in the antibacterial space with overlapping Gram-positive MRSA/S. pneumoniae indications.
• Pfizer (anti-infective portfolio): Big-pharma incumbent with a broad anti-infective franchise (linezolid/Zyvox, ceftaroline/Teflaro, and ongoing AMR initiatives). Broad incumbent serving the same prescribing physicians and patient populations for drug-resistant infections.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arietis